Thursday, Biogen Inc. (BIIB) announced compelling topline results from the Phase 2 CELIA study evaluating diranersen in participants with early Alzheimer's disease.
Notably, the study did not meet its primary endpoint assessing dose response for change from baseline on the Clinical Dementia Rating-Sum of Boxes at Week 76.
However, these results provide the first evidence from a randomized Phase 2 study of a tau-directed therapy demonstrating both robust biomarker impact and cognitive benefit in early Alzheimer's disease.
The company stated that the pre-specified analyses of cognitive endpoints showed slowing of clinical decline across all studied doses, particularly in participants receiving the lowest dose of diranersen, 60 mg administered every 24 weeks.
Diranersen also demonstrated robust reductions in both cerebrospinal fluid tau and tau pathology across all studied doses, with reductions maintained throughout the dosing period.
In the pre-market hours, BIIB is trading at $216.11, up 5.66 percent on the Nasdaq.
For comments and feedback contact: editorial@rttnews.com
May 15, 2026 15:25 ET Apart from the confirmation of Kevin Warsh as the next Fed chair, the main news on the economics front this week included key price data from the U.S. and the first quarter economic growth figures from major economies. Both consumer prices and producer costs have started to reflect the effect of supply shocks due to the Middle East conflict. In Europe, GDP data was in focus, while inflation data from China dominated the news flow in Asia.